 The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps Biotech stocks that hit 52-week lows Oct. 8. ABIOMED, Inc. NASDAQ: ABMD Adamas Pharmaceuticals Inc NASDAQ: ADMS Adaptimmune Therapeutics PLC ADR NASDAQ: ADAP AEterna Zentaris Inc. NASDAQ: AEZS Albireo Pharma Inc NASDAQ: ALBO Alpine Immune Sciences Inc NASDAQ: ALPN Arbutus Biopharma Corp NASDAQ: ABUS Aurinia Pharmaceuticals Inc NASDAQ: AUPH BioCryst Pharmaceuticals, Inc. NASDAQ: BCRX BIOLASE Inc NASDAQ: BIOL BioTelemetry Inc NASDAQ: BEAT CELYAD SAADR NASDAQ: CYAD Cerus Corporation NASDAQ: CERS Chimerix Inc NASDAQ: CMRX Clovis Oncology Inc NASDAQ: CLVS Goldman reiterated a Sell rating on the stock and cut the price target from 13 to 3. Corbus Pharmaceuticals Holdings Inc NASDAQ: CRBP CymaBay Therapeutics Inc NASDAQ: CBAY CytomX Therapeutics Inc NASDAQ: CTMX DelMar Pharmaceuticals Inc NASDAQ: DMPI DiaMedica Therapeutics Inc NASDAQ: DMAC Endologix, Inc. 